Panagora Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.52M Sell
3,408
-77
-2% -$35.9K 0.01% 632
2025
Q4
$1.58M Buy
3,485
+77
+2% +$33.2K 0.01% 624
2025
Q3
$1.33M Hold
3,408
0.01% 601
2025
Q2
$1.52M Sell
3,408
-11
-0.3% -$5.07K 0.01% 544
2025
Q1
$1.66M Sell
3,419
-6
-0.2% -$2.8K 0.01% 558
2024
Q4
$1.38M Sell
3,425
-9,910
-74% -$4.59M 0.01% 589
2024
Q3
$6.2M Sell
13,335
-35,219
-73% -$16.9M 0.03% 313
2024
Q2
$22.8M Sell
48,554
-51,616
-52% -$22.4M 0.11% 147
2024
Q1
$41.9M Sell
100,170
-133,961
-57% -$56.6M 0.22% 113
2023
Q4
$95.3M Buy
234,131
+32,612
+16% +$12M 0.53% 45
2023
Q3
$70.1M Buy
201,519
+105,608
+110% +$36.9M 0.44% 58
2023
Q2
$33.8M Buy
95,911
+60,495
+171% +$20.4M 0.2% 124
2023
Q1
$11.2M Sell
35,416
-75,526
-68% -$22.7M 0.07% 245
2022
Q4
$32M Buy
110,942
+34,885
+46% +$10.6M 0.21% 120
2022
Q3
$22M Sell
76,057
-22
-0% -$6.33K 0.15% 154
2022
Q2
$21.4M Sell
76,079
-108,918
-59% -$29.2M 0.14% 166
2022
Q1
$48.3M Sell
184,997
-89,263
-33% -$21.2M 0.26% 90
2021
Q4
$60.2M Sell
274,260
-115,628
-30% -$22.5M 0.32% 67
2021
Q3
$70.7M Buy
389,888
+90,980
+30% +$17.8M 0.38% 55
2021
Q2
$60.3M Buy
298,908
+71,477
+31% +$15M 0.32% 63
2021
Q1
$48.9M Buy
227,431
+185,337
+440% +$40.7M 0.27% 78
2020
Q4
$9.95M Sell
42,094
-49,947
-54% -$11.5M 0.06% 280
2020
Q3
$25M Buy
92,041
+14,368
+18% +$3.96M 0.16% 141
2020
Q2
$22.5M Buy
77,673
+97
+0.1% +$26.3K 0.14% 143
2020
Q1
$18.5M Sell
77,576
-553
-0.7% -$127K 0.13% 163
2019
Q4
$17.1M Sell
78,129
-182,691
-70% -$37M 0.08% 249
2019
Q3
$44.2M Sell
260,820
-478,708
-65% -$84.7M 0.2% 118
2019
Q2
$136M Sell
739,528
-116,764
-14% -$20.4M 0.61% 36
2019
Q1
$158M Sell
856,292
-479,597
-36% -$88.6M 0.7% 24
2018
Q4
$221M Sell
1,335,889
-118,675
-8% -$20.6M 1.03% 15
2018
Q3
$280M Buy
1,454,564
+499,019
+52% +$88.9M 1.06% 12
2018
Q2
$162M Buy
955,545
+73,360
+8% +$11.4M 0.64% 28
2018
Q1
$144M Buy
882,185
+61,554
+8% +$10.1M 0.57% 37
2017
Q4
$123M Buy
820,631
+62,303
+8% +$9.23M 0.46% 44
2017
Q3
$115M Buy
758,328
+145,142
+24% +$21.8M 0.46% 46
2017
Q2
$79M Buy
613,186
+163,633
+36% +$19.7M 0.32% 72
2017
Q1
$49.2M Sell
449,553
-447
-0.1% -$39.4K 0.2% 118
2016
Q4
$33.2M Buy
450,000
+18,064
+4% +$1.47M 0.15% 145
2016
Q3
$37.7M Sell
431,936
-4,337
-1% -$410K 0.18% 124
2016
Q2
$37.5M Sell
436,273
-12,639
-3% -$1.09M 0.19% 113
2016
Q1
$35.7M Sell
448,912
-6,766
-1% -$612K 0.18% 126
2015
Q4
$57.3M Sell
455,678
-184
-0% -$22.2K 0.28% 86
2015
Q3
$47.5M Buy
455,862
+44,757
+11% +$5.75M 0.25% 99
2015
Q2
$50.8M Buy
411,105
+28,519
+7% +$3.59M 0.25% 92
2015
Q1
$45.1M Buy
382,586
+33,919
+10% +$4.06M 0.23% 112
2014
Q4
$41.4M Buy
348,667
+121,717
+54% +$13.7M 0.21% 124
2014
Q3
$25.5M Buy
226,950
+199,610
+730% +$19M 0.12% 177
2014
Q2
$2.59M Sell
27,340
-6,397
-19% -$449K 0.01% 727
2014
Q1
$2.39M Buy
33,737
+13,109
+64% +$1.04M 0.01% 810
2013
Q4
$1.53M Buy
20,628
+3,803
+23% +$265K 0.01% 987
2013
Q3
$1.28M Sell
16,825
-12,306
-42% -$979K 0.01% 1012
2013
Q2
$2.33M Buy
+29,131
New +$2.15M 0.01% 727

Other funds holding VRTX

Panagora Asset Management's VRTX Position: Q1 2026 in Review

Panagora Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 2.2% in Q1 2026, selling an estimated $35.9K and leaving 3,408 shares worth $1.52M. The position accounts for 0.01% of the portfolio, ranked #632.

Panagora Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $280M in Q3 2018. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Panagora Asset Management held 3,408 shares of Vertex Pharmaceuticals worth $1.52M as of Q1 2026.
  • Panagora Asset Management sold 77 Vertex Pharmaceuticals shares in Q1 2026, an estimated $35.9K.
  • Vertex Pharmaceuticals made up 0.01% of Panagora Asset Management's portfolio in Q1 2026, its #632 holding.
  • Panagora Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Panagora Asset Management's Vertex Pharmaceuticals position peaked at $280M in Q3 2018.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Panagora Asset Management's 13F filing for Q1 2026, filed 14 May 2026.